Clinical Trial Update: TAS-102 and Anlotinib in ≥3 Lines mGC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating TAS-102 and Anlotinib in patients with gastric cancer who have received at least three prior lines of therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Zhejiang University | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN